Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17611842 | 0.77 | CA1 (0.43) | CA1CA2CA7CA13F2 | |
| SCHEMBL17849922 | 0.77 | F2 (0.37) | CA1CA2CA7CA13F2 | |
| SCHEMBL18573769 | 0.73 | ELANE (0.30) | — | |
| SCHEMBL8854036 | 0.71 | CA2 (0.39) | CA1CA2 | |
| SCHEMBL758884 | 0.69 | CA2 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL160 | 0.69 | CA2 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL758883 | 0.69 | CA2 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL2085247 | 0.69 | CA2 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL1533954 | 0.69 | F2 (0.36) | CA1CA2CA7CA13F2 | |
| SCHEMBL6448264 | 0.67 | CA2 (0.39) | CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109970760-B | ACC inhibitors and uses thereof | 吉利德阿波罗公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20140206671-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130090331-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2079740-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | VERTEX PHARMA (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8163732-B2 | Tricyclic heteroaryl compounds useful as inhibitors of Janus kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100081645-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-01 | — | — | US | disclosed |
| EP-2079740-A2 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | Vertex Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008079521-A2 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090331-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | JAK2, JAK1, JAK3 | CA1 4802/4885CA2 4066/4885CA7 4555/4885 |
| US-20100081645-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | JAK2, JAK1, JAK3 | CA1 4802/4885CA2 4066/4885CA7 4555/4885 |
| US-20140206671-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE | JAK2, JAK1, JAK3 | CA1 4802/4885CA2 4066/4885CA7 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.